LifeTechnologies為研究人員從科研到臨床應用的轉移做好準備
預先配置的工具和試劑，以支持細胞**的臨床轉化
Life Technologies公司（納斯達克代碼：LIFE）今天宣布了GIBCO?細胞**體系（CTS?）的誕生，它將提供生命科學行業中*廣陣容的產品線，以支持包括再生醫學在內的細胞**應用。該產品組合是專門為協助細胞**研究人員加速從科研到臨床應用的轉變而設計，將包括深層而廣泛的Invitrogen設備和試劑。
如今，細胞**研究人員往往需要花費大量的時間和**，將推動一個細胞**概念從實驗室環境轉移到臨床所需的工具和試劑進行組合和驗證，使之成為一個符合監管且可獲得高度支持的過程。基于細胞的**有著數以千計的潛在應用，有望應對尚有待解決的醫療需求，包括神經障礙、心臟病、自體****、傳染病，以及傳統**不起作用的組織修復。隨著再生醫學領域經歷爆炸式的增長，在未來的15年將從16億美元增長到150-200億美元1，LifeTechnologies正在打造一個打包的工具和試劑組合以應對這個挑戰，并協助研究人員加速將有潛力的方案轉移到臨床環境的過程。
“文檔是將**的細胞**帶到臨床的關鍵之一，”加利福尼亞州Duarte希望城生物醫學和遺傳學中心的主管，應用技術開發中心的**副總裁和創始人LarryCouture博士認為。“在臨床前開發階段以及臨床試驗過程中的更深入階段，有適當的質量體系，合適的文檔以及穩定的供應鏈很關鍵。”
CTS產品組合將提供培養基、試劑、酶、緩沖液、生長因子、分選磁珠和磁鐵，以及完整流程方案中的其他組成部分。高質量的材料將提供容易獲取的文獻資料，如分析證明書和原產地證明書。此外，將為產品提供*高程度的技術支持、監管支持以及網絡支持。
“我們憑借我們的專業知識以及廣泛而深入的產品組合來創建細胞**的流程方案，它將協助研究人員更快更高效地從科研應用進入到臨床，同時增強患者的**性，”LifeTechnologies細胞**系統的總經理PaulPickering談到。“我們期望所提供的這些產品能讓我們與這個領域的核心***建立合作，并在他們準備將細胞**概念轉移到臨床時協助他們減輕驗證工具和試劑的負擔，這*終將改善人類狀況，并解決尚未滿足的醫療需求。”
科學顧問新市場回顧，引用自Fierce Biotech 2010年4月23日的文章。
關于Life Technologies (http://www.lifetechnologies.com) LifeTechnologies公司（納斯達克代碼：LIFE）是一家致力于改善人類環境的全球生物技術公司。我們的儀器、耗材和服務可協助研究者加速科學探索與開發，從而讓生命變得更加美好。我們的客戶遍及生物學各個領域，努力加速推進個性化**、再生科學、分子診斷、農業和環境的研究以及21世紀的法醫鑒定。生命科技公司2009年的銷售額為33億美元，全球雇員約為9000人，遍及160個國家，并擁有將近3900項知識產權**及專有許可證。LifeTechnologies公司由Invitrogen公司和AppliedBiosystems公司合并而成，制造體外診斷產品和僅供研究的產品。更多關于我們如何起作用的信息，請訪問網站www.lifetechnologies.com。
Life Technologies的**聲明
本新聞稿包含關于我們預期結果的前瞻性陳述，且涉及多種風險和不確定因素。本新聞稿中的部分內容，包括但不限于，行業趨勢、LifeTechnologies的業務計劃、目標、預期和戰略的陳述，均包含受各種風險和不確定因素影響的前瞻性陳述，這些風險和不確定因素可能導致實際結果和事件與前瞻性陳述中明示或暗示的有重大差異。任何不屬于歷史事實的陳述均為前瞻性陳述。可以通過一些特定用詞，如“相信”、“計劃”、“意圖”、“預期”、“目標”、“估計”、“期望”，和/或將來時態、條件句結構（如“將”、“可能”、“可以”、“應當”等）或類似的表達方式，來識別一部分前瞻性陳述。可能引發實際結果與前瞻性陳述有重大差異的一些重要因素，在LifeTechnologies向美國證券交易委員會提交的文件中皆有詳述。LifeTechnologies不承擔任何更新或修改此類前瞻性陳述，以反映后續事件或情形的義務。
LifeTechnologies Readies Researchers for Transition from Benchtop toBedside
Tools and reagents pre-configured to supportcell therapy clinical translation
CARLSBAD, Calif. – June 16, 2010 – Life Technologies Corporation(NASDAQ: LIFE) today announced the formation of GIBCO? Cell Therapy Systems (CTS?), which will offer the life scienceindustry’s widest array of products to support cell therapyapplications, including regenerative medicine. Specificallydesigned to help cell therapy practitioners accelerate thetransition from research to clinical applications, the productportfolio will include a broad and deep offering of Invitrogendevices and reagents.
Cell therapy practitioners today spend a lot of time and moneyassembling and qualifying the tools and reagents required to move acell therapy concept from a laboratory environment to the clinic ina regulatory compliant and highly supported process. Cell-basedtherapies have hundreds of potential applications addressing unmetmedical needs, including neurological disorders, heart disease,cancer, auto-immune disease, infectious disease, as well as tissuerepair where conventional pharmaceuticals may be ineffective. Withthe regenerative medicine field experiencing explosive growth, from$1.6 billion to $15 - $20 billion over the next 15 years1, LifeTechnologies is building a portfolio of bundled tools and reagentsto address this challenge and help researchers accelerate theprocess of moving their potential solutions into a clinicalenvironment.
“Documentation is a critical aspect of bringing novel celltherapies to the clinic,” said Dr. Larry Couture, Senior VicePresident and Founding Director of the Center for AppliedTechnology Development; Director for the Center for Biomedicine andGenetics at the City of Hope in Duarte, California. “Having properquality systems in place, appropriate documentation, and a stablesupply chain is critical, both in the pre-clinical developmentphase, as well as further down the road during clinicaltrials.”
The CTS product portfolio will provide media, reagents, enzymes,buffers, growth factors, selection-beads and magnets, and othercomponents of integrated workflow solutions. The high-qualitymaterials will come with easily accessible documentation, such ascertificates of analysis and certificates of origin. Moreover, theproducts will be backed up with the highest level of technical,regulatory and web-based support.
“We’ve leveraged our expertise, as well as our broad and deepproduct portfolio to create workflow solutions for cell therapythat will help investigators move their research applications intothe clinic more quickly and efficiently, while enhancing patientsafety,” said Paul Pickering, General Manager of Cell TherapySystems at Life Technologies. “We anticipate that this offeringwill enable us to form collaborations with key industry leaders,and help reduce their burden in qualifying tools and reagents asthey prepare to move their cell therapy concepts into the clinic,which will ultimately help improve the human condition and addressunmet medical need.”
1 Scientia Advisors new market review, quoted in April 23, 2010article from Fierce Biotech.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a globalbiotechnology tools company dedicated to improving the humancondition. Our systems, consumables and services enable researchersto accelerate scientific exploration, driving to discoveries anddevelopments that make life even better. Life Technologiescustomers do their work across the biological spectrum, working toadvance personalized medicine, regenerative science, moleculardiagnostics, agricultural and environmental research, and 21stcentury forensics. Life Technologies had sales of $3.3 billion in2009, employs approximately 9,000 people, has a presence inapproximately 160 countries, and possesses a rapidly growingintellectual property estate of approximately 3,900 patents andexclusive licenses. Life Technologies was created by thecombination of Invitrogen Corporation and Applied Biosystems Inc.,and manufactures both in-vitro diagnostic products and research useonly-labeled products. For more information on how we are making adifference, please visit our website:http://www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about ouranticipated results that involve risks and uncertainties. Some ofthe information contained in this press release, including, but notlimited to, statements as to industry trends and LifeTechnologies'''''''''''''''''''''''''''''''' plans, objectives,expectations and strategy for its business, containsforward-looking statements that are subject to risks anduncertainties that could cause actual results or events to differmaterially from those expressed or implied by such forward-lookingstatements. Any statements that are not statements of historicalfact are forward-looking statements. When used, the words"believe," "plan," "intend," "anticipate," "target," "estimate,""expect" and the like, and/or future tense or conditionalconstructions ("will," "may," "could," "should," etc.), or similarexpressions, identify certain of these forward-looking statements.Important factors which could cause actual results to differmaterially from those in the forward-looking statements aredetailed in filings made by Life Technologies with the Securitiesand Exchange Commission. Life Technologies undertakes no obligationto update or revise any such forward-looking statements to reflectsubsequent events or circumstances.
Products are For Research Use Only. Not intended for any animal orhuman therapeutic or diagnostic use.
Life Technologies Contact
